Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide – might not be able to ...

Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

MALVERN, Pa. and KENILWORTH, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Centocor, Inc. and Schering-Plough Corporation today announced that the European Commission has ...

Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Centocor have warned healthcare professionals via letter regarding risks of hepatotoxicity and pneumonia associated with the use of ...

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid ...

INCHEON, South Korea--(BUSINESS WIRE)--A new post-hoc analysis of a pivotal phase III randomised controlled clinical trial shows that the subcutaneous (SC) formulation of infliximab, Remsima ® (CT-P13 ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to ...